Counterconditioning as treatment for pain

Gepubliceerd: 28-11-2019 Laatst bijgewerkt: 15-05-2024

The primary objective of the current pilot study is to investigate the feasibility of a 6-week counterconditioning treatment method aimed to reduce pain in patients with fibromyalgia. This will be assessed by looking at the drop-out rate; by…

Ethische beoordeling	Positief advies
Status	Werving gestart
Type aandoening	-
Onderzoekstype	Interventie onderzoek

Samenvatting

ID

NL-OMON27907

Bron
NTR

Verkorte titel
TBA

Aandoening

The study is conducted in a sample of patients with fibromyalgia

Ondersteuning

Primaire sponsor: Leiden University
Overige ondersteuning: Netherlands Organization for Scientific Research (NWO) - Vici grant

Onderzoeksproduct en/of interventie

Uitkomstmaten

Primaire uitkomstmaten

The feasibility of the intervention (e.g., satisfaction of participants, drop-out rate).

Descriptive statistics (means, standard deviations, etc.) of relevant variables will be calculated.

Toelichting onderzoek

Achtergrond van het onderzoek

Treatment opportunities for persistent physical symptoms, such as chronic pain, are currently limited. It is suggested that nocebo effects (i.e. adverse outcomes not attributable to an active treatment, putatively mediated by negative expectations) can negatively influence symptom progression. With procedures of counterconditioning, combined with verbal suggestions, previously learned associations (causing negative expectations) between different stimuli can be reversed. Therefore, counterconditioning could provide an innovative method for reducing physical symptoms. In the current study, the feasibility of using counterconditioning methods as a novel treatment method for reducing pain symptoms will be examined in a clinical population of fibromyalgia patients.

Doel van het onderzoek

The primary objective of the current pilot study is to investigate the feasibility of a 6-week counterconditioning treatment method aimed to reduce pain in patients with fibromyalgia. This will be assessed by looking at the drop-out rate; by measuring participant's satisfaction with the intervention; by examining what, according to the participants, is causing the possible increase and reduction of experimentally evoked pressure pain in the test phase of (counter)conditioning (e.g., the TENS device, the placebo or nocebo effect); by examining the amount of experimentally-evoked pressure pain reported during the test phase of counterconditioning, whether this reduces over time, as well as the speed of this reduction.

Additionally, we will explore whether an induced nocebo effect in the intervention group can be successfully reduced (or even reversed) by comparing the change in the conditioned nocebo effect from the test phase of conditioning (session 1) to the counterconditioned nocebo effect from the test phase of counterconditioning (session 6 + 3- and 6-month follow-up) in the intervention group and the control group. We will also explore whether these effects generalize to clinical pain symptoms. Last, we will explore whether there is a relationship between individual characteristics, such as pain catastrophizing and participants' expectations about the intervention, and the changes due to counterconditioning.

Onderzoeksopzet

9 lab sessions (intake session, 6-week intervention, 3-and 6-month follow-up). Each lab session lasts approximately 45 minutes, with the exception of the intake session and the first session, which last 30 minutes and two hours, respectively. The homework exercises will take approximately 10 minutes per day.

Onderzoeksproduct en/of interventie

Counterconditioning methods will be used for desensitization of pain symptoms in the intervention group. Participants in the intervention group will participate in a conditioning procedure once during session 1, in order to ensure that a specific association with the primary symptom of pain is established that can be counterconditioned.

During conditioning and counterconditioning, the learning phase consists of 20 pressure stimuli, which are either moderately painful (nocebo conditioning) or non-painful (counterconditioning) during the experimental trials and slightly painful during control trials. In the control group, all stimuli will be given in a randomized order. The test phase for all groups consists of 6 trials with slightly painful pressure stimuli presented in both experimental and control trials.
In sessions 2-6, only the (sham) counterconditioning procedure will be repeated, meaning only non-painful and slightly painful stimuli will be used.

Participants in both groups are asked to rate their levels of pain after every pressure stimulus on an NRS, which will later be used to calculate the individual reduction of the nocebo effect.

Participants will be given homework exercises to strengthen the intervention and promote generalization of symptom desensitization to everyday life.

Contactpersonen

Publiek

Leiden University
Andrea Evers

+31 71 527 6891

Wetenschappelijk

Leiden University
Andrea Evers

+31 71 527 6891

Deelname eisen

Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

Female volunteers (≥ 18 years), with a diagnosis of fibromyalgia (FM) provided by a general practitioner or medical specialist, with current pain complaints as a result of FM, and with a good understanding of written and spoken Dutch.

Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

Physical conditions other than FM explaining pain symptoms, severe psychiatric comorbidities that are not related to the fibromyalgia symptoms (e.g., schizophrenia), pregnancy or lactation, refusal to remove artificial nails, nail polish, or any other substance covering the thumbnails, having metal-containing implants in the non-dominant arm (including non-removable piercings), carrying a pacemaker or implanted pumps, injuries/open wounds on the non-dominant arm.

Onderzoeksopzet

Opzet

Type:	Interventie onderzoek
Onderzoeksmodel:	Parallel
Toewijzing:	Gerandomiseerd
Blindering:	Open / niet geblindeerd
Controle:	Placebo

Deelname

Nederland

Status:	Werving gestart
(Verwachte) startdatum:	02-12-2019
Aantal proefpersonen:	36
Type:	Verwachte startdatum

Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)

Wordt de data na het onderzoek gedeeld: Ja

Toelichting
Coded research data will be made publicly available in an online data repository after publication of the research findings.

Ethische beoordeling

Positief advies
Datum: 28-11-2019
Soort: Eerste indiening

Registraties

Opgevolgd door onderstaande (mogelijk meer actuele) registratie

ID: 55456
Bron: ToetsingOnline
Titel:

Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

In overige registers

Register	ID
NTR-new	NL8189
CCMO	NL66812.058.18
OMON	NL-OMON55456

Resultaten